United States: Patent Owner Must Pay Accused Infringer's $14 Million Attorney Fees And Costs Because Of Prosecution And Litigation Misconduct


A New Jersey court ordered a patent owner to pay $14 million to a company it sued for patent infringement to reimburse that company for its attorney fees and costs in the litigation filed by the patent owner.  The court based its order on the patent owner's misconduct before the Patent and Trademark Office and the patent owner's baseless positions during the litigation.

Courts may award attorney fees and costs to a prevailing party in patent infringement suits deemed to be "exceptional." To determine if a case is exceptional, courts extensively analyze the facts and consider the totality of the circumstances. Circumstances that commonly contribute to finding a case exceptional include advancing frivolous or baseless claims, inequitable conduct during either litigation or prosecution before the patent office, and other conduct suggesting bad faith.

The New Jersey court recently granted a defendant in a patent infringement case $14 million in attorney fees and costs due to the exceptional nature of a decade-long infringement litigation advanced by Howmedica Osteonics.


In 2005, Howmedica sued Zimmer for infringing four patents covering methods for improving the longevity of polymer-based medical implants. Over eleven years of litigation, federal courts invalidated each of Howmedica's asserted patents. After the Federal Circuit struck down the last patent in 2016, Zimmer moved for an award of attorney fees and costs.

The Howmedica Decision

The New Jersey court found the case exceptional and awarded Zimmer its attorney's fees and costs based on Howmedica's conduct before the United States Patent and Trademark Office and a baseless litigation position taken by Howmedica. In finding the case exceptional and warranting payment of attorney fees, the court relied on several factors: (1) bad faith in selectively disclosing data and evading the patent examiner's concerns, (2) misrepresenting a witness as being independent of the patent owner, (3) presenting testimony discrediting their own prior contrary positions, (4) presenting testimony that was facially contradictory, (5) taking unreasonable patent claim constructions and (6) shifting patent claim constructions during litigation.

Bad Faith: Selectively Disclosing Data and Evading Examiner Concerns

To overcome a prior art obviousness rejection presented during prosecution leading to the asserted patents, Stryker Technologies (Howmedica's parent corporation and owner of the patent applications during prosecution) submitted a declaration by Dr. Aiguo Wang asserting that the claimed medical implant invention supplied unexpectedly improved wear characteristics.

The examiner maintained his rejection, unconvinced that the comparative data submitted by Dr. Wang represented a statistically significant degree of improvement.

Instead of addressing the examiner's concerns about the claimed method's alleged degree of improvement, Dr. Wang, in a second declaration, maligned the wear characteristics of the asserted prior art.  Based on these representations, the examiner granted the patent.

Zimmer eventually discovered that Dr. Wang selectively disclosed his comparative testing data to the USPTO, omitting data supporting the examiner's obviousness rejection and data undermining the degree of improvement asserted by Dr. Wang to overcome the obviousness rejection.  In the Court's opinion, Dr. Wang's actions were "disingenuous" and "likely a violation of [applicant's] broad disclosure requirements before the [USPTO]."  Moreover, it described Dr. Wang's evasion of the examiner's concerns about the statistical significance of the purported wear-improvement as indicative of an "intent to deceive the [USPTO]."  According to the court, however, neither action amounted to inequitable conduct because Zimmer could not prove that the patents would not have issued but for the withheld data.  But, taken as a whole, Dr. Wang's actions suggested that Howmedica's predecessor in interest prosecuted before the USPTO in "bad faith." 

Mischaracterizing Declarant's Relationship to Applicant

Though Dr. Wang's declarations recorded that he was an employee of Howmedica, he was, in fact, employed by the owner of the patent applications, Stryker Technologies.  Because Stryker had only recently purchased Howmedica, USPTO examiners would not have been aware of the relationship between Stryker and Howmedica. By indicating that the declarant worked at Howmedica, the applicant misrepresented Dr. Wang as an independent expert. Though a declarant's failure to disclose his or her relationship with applicant is a common basis for a finding of inequitable conduct, the Court eschewed an inequitable-conduct analysis, satisfied that Dr. Wang's misrepresentation indicated exceptionality.

Inequitable Conduct: Affiant's Statements Contradicting His Prior Publications

In response to an obviousness rejection of a claimed solubility range based on inherency, the applicant again submitted a declaration from Dr. Wang. Dr. Wang asserted that the reference method was comparable to a conventional method that produced solubility values outside of the claimed range. Based on this assertion, the examiner allowed the claimed invention. Years earlier, however, Dr. Wang published data contradicting his declaration. Despite Dr. Wang's assertions that he "did not recall" the previously-published data, the Court found that the "single most reasonable inference" was that Dr. Wang intended to deceive the USPTO. Moreover, because the USPTO ultimately relied on these previously-published references to reject the patent during reexamination, the Court found that Dr. Wang's failure to disclose them was material to patentability. Thereby, the Therasense  standard of inequitable conduct was satisfied.

Howmedica's Statements Discrediting Its Own prior Publications Used as References During Reexam

In 2009, during a reexamination of one of the four asserted patents, Howmedica produced a declaration from a Howmedica employee, Dr. Streicher. The declaration discredited a publication—asserted to reject the claimed invention—that he had authored. This previous publication taught a method for reducing oxidation by 40%. In his declaration, Dr. Streicher asserted that one of ordinary skill would not have been motivated to use his previously-disclosed method because a 40% reduction in oxidation was "negligible." According to the court, this facial contradiction was "an unreasonable position" that also supported a finding of an exceptional case.

The final factor contributing to the court's finding of exceptionality concerned Howmedica's shifting claim construction. During prosecution and early in litigation, Howmedica (and its predecessor in interest, Stryker) adopted a first construction of a claimed limitation. One year into litigation, however, Howmedica adopted a second construction to distinguish its claims from a newly-found reference. In doing so, Howmedica demonstrated to the Court that it recognized the reference as fatal to its patent. Howmedica's persistence in claiming infringement in the face of an invalidating reference amounted to what the Court considered litigation misconduct. That Howmedica's position was "baseless" and "objectively unreasonable" was emphasized by the fact that their second construction was equally invalid for being incurably indefinite.

Strategy and Conclusion

Inequitable conduct and other misconduct, like omitting relevant test data and failing to fully disclose a declarant's relationship to the application, may support a finding of exceptional behavior in infringement litigation, warranting an award of attorney's fees and costs.

Further Information
The Howmedica decision can be found here.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Events from this Firm
23 Sep 2018, Seminar, Chicago, United States

Finnegan is a sponsor of the Intellectual Property Owners Association Annual Meeting, supporting the Women in IP Networking Brunch.

26 Sep 2018, Webinar, Washington, DC, United States

This latest series of webinars will explore emerging trends in the changing intellectual property (IP) legal environment in Europe and the United States.

26 Sep 2018, Webinar, Washington, DC, United States

This latest series of webinars will explore emerging trends in the changing intellectual property (IP) legal environment in Europe and the United States.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions